Three questions about study on treatments for pyoderma gangrenosumBMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5113 (Published 30 September 2015) Cite this as: BMJ 2015;351:h5113
- Noha Elshimy, doctor1
- 1City Hospital, Birmingham, UK
I have a few questions and critiques for the authors about this excellent study of treatments for pyoderma gangrenosum.1
Firstly, why were patients who had taken rosuvastatin excluded from the study, and what would have been the perceived effects of this on your results?
Secondly, the study was not double blinded. Patients and …